|View printer-friendly version|
|Infinity to Present IPI-145 Phase 1 Clinical Data at ASH|
– Company to Host Investor Reception at ASH on
“In this ongoing Phase 1 trial, we are very encouraged by the activity
observed at the three lowest dose levels of IPI-145 evaluable for
response, including responses in patients with chronic lymphocytic
leukemia, indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. We
have continued to make progress in this study since submitting our
abstract in July. Specifically, dose escalation is still ongoing, and we
expect to soon complete patient enrollment in our first expansion cohort
evaluating IPI-145 at a dose of 25 mg twice daily in the same
indications for which we have seen responses,” stated
“IPI-145 has a number of distinct features, including high potency against PI3K-delta, the ability to inhibit PI3K-gamma and dose proportional pharmacokinetics. We believe that these properties have the potential to translate into benefits for patients and establish IPI-145 as the best-in-class PI3K inhibitor in hematologic malignancies as well as inflammation,” Dr. Adams continued.
Infinity will also host a reception on
Poster Presentation Details
The abstract accepted for presentation at ASH includes an evaluation of
the safety, activity and pharmacokinetics of IPI-145 as of
Responses were observed at each of the lowest dose levels of IPI-145 evaluated, including 8 mg BID, 15 mg BID and 25 mg BID, in patients with chronic lymphocytic leukemia (2 partial responses in 3 patients), indolent non-Hodgkin’s lymphoma (1 complete response in 2 patients) and mantle cell lymphoma (1 partial response in 1 patient), for a total of 4 responses among 6 evaluable patients with either chronic lymphocytic leukemia, indolent non-Hodgkin’s lymphoma or mantle cell lymphoma. Responses were not observed among five evaluable patients with aggressive non-Hodgkin’s lymphoma or multiple myeloma.
The Phase 1 trial is evaluating patients with B-cell and T-cell malignancies in the ongoing dose escalation.
Infinity is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase and heat shock protein 90 are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company’s website at www.infi.com.
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding the expected timing
for reporting data regarding IPI-145, the therapeutic potential of
IPI-145 and the potential for IPI-145 to be the best-in-class PI3K
inhibitor in hematologic malignancies and inflammation. Such statements
are subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from the
company’s current expectations. For example, there can be no guarantee
that Infinity will report data in the timeframes it has estimated, that
any product candidate Infinity is developing will successfully complete
necessary preclinical and clinical development phases or that
development of any of Infinity’s product candidates will continue.
Further, there can be no guarantee that any positive developments in
Infinity’s product portfolio will result in stock price appreciation.
Management’s expectations could also be affected by risks and
uncertainties relating to: Infinity’s results of clinical trials and
preclinical studies, including subsequent analysis of existing data and
new data received from ongoing and future studies; the content and
timing of decisions made by the U.S.